摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-{1-[3-(3,4-dimethoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one | 1448717-67-6

中文名称
——
中文别名
——
英文名称
2-{1-[3-(3,4-dimethoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one
英文别名
2-[1-[3-(3,4-dimethoxyphenyl)azetidin-1-yl]ethyl]-7-(oxan-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one
2-{1-[3-(3,4-dimethoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one化学式
CAS
1448717-67-6
化学式
C23H29N5O4
mdl
——
分子量
439.514
InChiKey
STFANZPHCLVNIR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    32
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    90.2
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • [EN] PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE<br/>[FR] INHIBITEURS DE PDE9 COMPRENANT UN SQUELETTE IMIDAZOTRIAZINONE
    申请人:LUNDBECK & CO AS H
    公开号:WO2013110768A1
    公开(公告)日:2013-08-01
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula(l) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种式(I)化合物,用于治疗患有精神障碍的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。
  • PDE9 inhibitors with imidazo triazinone backbone
    申请人:H. Lundbeck A/S
    公开号:US20150045348A1
    公开(公告)日:2015-02-12
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。
  • PDE9 Inhibitors with Imidazo Triazinone Backbone
    申请人:H. Lundbeck A/S
    公开号:US20160213674A1
    公开(公告)日:2016-07-28
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    本发明涉及一种PDE9酶抑制剂化合物。本发明提供一种制药组合物,包括本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备式(I)化合物的过程。本发明还提供了一种治疗神经退行性疾病的方法,包括向患者施用式(I)化合物的治疗有效量。本发明还提供了一种式(I)化合物,用于治疗精神障碍的方法,包括向患者施用式(I)化合物的治疗有效量。
  • PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE
    申请人:H. Lundbeck A/S
    公开号:EP2807163B1
    公开(公告)日:2017-03-22
  • PDE9- INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE
    申请人:H. Lundbeck A/S
    公开号:EP3178820B1
    公开(公告)日:2017-12-20
查看更多

同类化合物

阿昔替酯 螺喹唑啉 苯并[g][1,2,3]三唑并[4',5':5,6]吡啶并[2,1-b]喹唑啉-13(2H)-酮 脱氢利培酮 盐酸曲林菌素 甲硫利马唑 甲基8-乙基-2-甲氧基-5-氧代-5,8-二氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基8-乙基-2-(甲硫基)-5-氧代-5,6,7,8-四氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基2-乙氧基-8-乙基-5-氧代-吡啶并[6,5-d]嘧啶-6-羧酸酯 溴他替尼 泮托拉唑杂质DF 氨甲酸,[(2R,3E)-2-羟基-3-戊烯基]-,1,1-二甲基乙基酯(9CI) 柱孢藻毒素 曲美替尼 曲美替尼 曲喹辛 异噻唑并[5,4-d]嘧啶,3-亚硝基-(9CI) 帕潘立酮棕榈酸酯 帕潘立酮杂质7 帕潘立酮杂质16 帕潘立酮杂质 帕潘立酮杂质 帕潘立酮去氟杂质 帕潘立酮Z-异构体 帕潘立酮 帕泊昔布杂质117 帕布昔利布杂质46 帕博西尼杂质S 帕利哌酮杂质05 帕利哌酮杂质03 帕利哌酮杂质02 帕利哌酮十四酸酯 帕利哌酮N-氧化物 布喹特林 巴马斯汀 奥卡哌酮 多夸司特 嘧啶并[4,5-d]嘧啶-2,4,5(1H,3H,6H)-三酮,7-乙氧基-1,3-二甲基-6-(苯基甲基)- 吡曲克辛 吡嘧司特钾 吡嘧司特 吡啶并[4,3-d]嘧啶-4(1H)-酮,4,5,6,7-四氢-6-甲基-2-苯基- 吡啶并[4,3-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,4-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,2-d]嘧啶-4(3H)-酮,3-甲基-2-(甲基氨基)- 吡啶并[3,2-d]嘧啶-4(3H)-酮 吡啶并[3,2-d]嘧啶-4(1H)-酮,2,3-二氢-3-(2-羟基苯基)-2-硫代- 吡啶并[3,2-d]嘧啶-2,4(1H,3H)-二酮 吡啶并[2,3-d]嘧啶-7(8h)-酮,2,6-二溴-8-环戊基-5-甲基- 吡啶并[2,3-d]嘧啶-7(8H)-酮